Loading stock data…
Verastem, Inc. (VSTM)
$3.78+0.33 (+9.57%)
Market ClosedLast close Jun 26
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Verastem, Inc. in the Healthcare sector is trading at $3.78 with a market capitalization of $318M. Wall Street consensus targets $15.12 (8 analysts), implying a +300.1% move over the next 12 months. The stock is currently near its 52-week low of $3.43, remaining 45.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +300.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $18.67M↑ | $17.54M↑ | $11.24M↑ | $2.14M | $0 |
| Gross Profit | $15.62M↑ | $14.64M↑ | $9.28M↑ | $1.69M | $0 |
| Operating Income | -$44.90M↓ | -$41.48M↓ | -$40.72M↑ | -$43.76M↑ | -$44.17M |
| Net Income | -$36.59M↓ | -$32.92M↑ | -$98.52M↓ | -$25.93M↑ | -$52.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$318.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-237.18%
Volume
Today's trading volume
8.03M
Recent News
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Verastem, Inc. (NASDAQ:VSTM) is one of the most promising stocks on our list. TheFly reported on June 17 that VSTM Oncology announced updated safety and efficacy findings from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose cohort. The […]
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
Verastem (VSTM) said late Tuesday that preliminary data from its ongoing Phase 1/2 TARGET-D 101 tria
VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda
The Fast Track designation is designed to help promising medicines for serious diseases reach patients faster by allowing more frequent contact with regulators and potentially quicker review.
Verastem (VSTM) Loses 34.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Verastem (VSTM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Verastem, Inc. (NASDAQ:VSTM) Just Released Its First-Quarter Earnings: Here's What Analysts Think
It's been a mediocre week for Verastem, Inc. ( NASDAQ:VSTM ) shareholders, with the stock dropping 18% to US$4.89 in...